The Association Between Migraine Medication Type, Pain Severity, and Genetic Factors: A Cross-Sectional and Prospective Analysis

Terrmin

HT25

Beskrivning

Background
Have you ever wondered why some people with migraine experience severe pain while others respond better to the same treatments? Migraine is very prevalent and disabling, affecting roughly one billion individuals worldwide. Although therapies range from triptans to CGRP antagonists, not everyone benefits equally. The overall genetic composition may help explain these differences in pain levels and medication responses. However, more evidence is needed to understand precisely how your genetic background translates to real-world medication use and migraine severity.

Aim
This project will utilize data from the UK Biobank to:
1. Investigate whether individuals with a higher genetic predisposition to migraine are more likely to use specific types of medication (e.g., preventive vs. acute therapy).
2. Assess the link between genetic factors and migraine pain severity in a large population-based setting.
3. Determine whether genetic predisposition can predict changes in medication use and pain severity over time.

Methods
• Data Source: We will use the UK Biobank, a large-scale database providing comprehensive genetic, clinical, and self-reported information on ~500,000 participants.
• Analytical Approach: We will develop statistical models to explore how genetic predisposition correlates with medication choice and pain levels and their evolution across the study period. We will control for demographic factors such as age, sex, BMI, and relevant comorbidities to ensure robust findings. We will employ both a cross-sectional approach (one point in time) and a prospective follow-up (tracking changes over time).

Projektets upplägg kräver studentens närvaro på plats måndag till fredag under hela arbetsdagen. Detta för att säkerställa full delaktighet i det dagliga arbetet och möjliggöra ett nära samarbete med projektgruppen.

Huvudområde

Farmaceutisk vetenskap

Ämne

Farmakologi

Typ

Registerstudie

Företag

Läkemedelsverket

Ort/Plats

Uppsala

Handledarens namn

Jessica Mwinyi och Linda Wåhlström

Handledarens e-post

jessica.mwinyi@lakemedelsverket.se; linda.wahlstrom@lakemedelsverket.se

Institution

Institutionen för farmaceutisk biovetenskap

Program

Apotekarprogrammet

Kurs

Fördjupningsprojekt i farmaceutisk farmakologi 30 hp - 3FF293

Omfattning/hp

30hp

Hur många studenter kan antagas för detta projekt?

1

© 2022 Uppsala universitet | Teknisk support